# CONTENTS

## SECTION 1: CLINICAL AND PREVENTIVE CARDIOLOGY


1. **Development of Cardiology in India: Where are We Today?** ..... 3
S Padmavati

*Cardiac situation* 3
*Medical manpower* 3
*Cardiac manpower* 4
*Cardiothoracic surgery* 4
*Training programs* 4
*Centers for tertiary care* 4
*Comparison with industrialized countries* 4
*Quality of cardiac care* 4
*Research* 4
*Prevention* 5

2. **Antiplatelets and Antithrombotics after DES: What Next?** ..... 6
Parneesh Arora, Upendra Kaul

*New antiplatelet drugs* 6
*Antithrombotic agents* 6

3. **Impact of Kidney Disease on the Outcome and Management of Acute Coronary Syndrome** ..... 11
Binoy John

*Impact of acute kidney injury on acute coronary syndrome* 11
*Impact of chronic kidney disease on acute coronary syndrome* 12
*Antiplatelet agents in chronic kidney disease patients with acute coronary syndrome* 15
*Anti-ischemic agents and statins in chronic kidney disease patients with acute coronary syndrome* 15
*Antithrombotic therapy in chronic kidney disease patients with acute coronary syndrome* 18

4. **Antiplatelet Drug-resistance in Asian Population** ..... 22
G Vijayaraghavan, Sadath Pareed

*Mechanism* 22
*Genetic variability on platelet function test* 24
*Predicting adverse cardiovascular events* 24
*Treating aspirin and clopidogrel resistance* 24
*Future direction and clinical consideration* 25

5. **Gold or Old Standard: New Insights on Aspirin in Cardiovascular Diseases (CVD) Prevention** ..... 27
Mukesh Kumar Sharma, SK Kaushik

*Aspirin in primary prevention of CVD* 27
*Aspirin for primary prevention in specific populations* 28
*Optimal dose and preparation of aspirin* 29

*Summary of recommendations on prophylactic aspirin use (various organizations)* 29
*Guidelines and recommendations: patients with diabetes* 29

**6. Changing Landscape of Oral Anticoagulants: The Last Pieces of the Puzzle** ..... 31
Anjan Lal Dutta, Ratnesh N Rokade, Rajarshi Dutta

*Dabigatran* 31
*Rivaroxaban* 31
*Apixaban* 32
*Edoxaban* 32
*Concomitant use of NOAC and digoxin* 32
*Transition to oral vitamin K antagonists from novel oral anticoagulants* 32
*Bleeding in patients recieving novel oral anticoagulants* 32
*Acute coronary events and novel oral anticoagulants* 33
*Renal impairment and novel oral anticoagulants* 34
*Warfarin versus novel oral anticoagulants: a revisit* 34

**7. Top Ten Most Promising New and Future Therapies in Cardiology: Status Report 2014** ..... 36
AK Pancholia

*Nonpharmacological therapies* 36
*Pharmacotherapies* 39
*Cell therapy* 41
*Others* 43

**8. A Cardiologist's Viewpoint on Gliptins: The New Star on the Horizon of Diabetes** ..... 46
PC Manoria, Pankaj Manoria, Piyush Manoria, SK Parashar

*Diabetes: a cardiovascular disease* 46
*Diabetes, incretin defect and gliptins* 46
*Gliptins: a cardiologists view point* 47

**9. Statins as Primary Preventive Strategy** ..... 50
Rajan Joseph Manjuran

*Cardiovascular disease: the global burden* 50
*Cardiovascular disease in India* 50
*Current use of statins in primary prevention of CVD* 50

**10. Management of Atherogenic Dyslipidemia Triad: Indian Perspective** ..... 54
Sivakadaksham, Sameer Dani, Prashant Advani

*Common link between dyslipidemia/diabetes and CVD: insulin resistance syndrome* 54
*Pathogenesis of atherogenic dyslipidemia triad of insulin resistance and type 2 diabetes* 54
*Lipid triad accelerates atherosclerosis via multiple mechanisms* 55
*Management of dyslipidemic triad* 56

**11. Lipid Management Beyond Statins Targeting HDL and TG: Challenges 2014** ..... 59
Saumitra Ray

*Etiopathogenesis of diabetic dyslipidemia* 59
*Concept of therapy of atherogenic dyslipidemia* 60

**12. Management of Hypertriglyceridemia and Cardiovascular Risk Reduction** ..... 66
RR Mantri, C Raghu, Sanjeev K Sharma

*Prevalence of hypertriglyceridemia with Indian perspective* 66
*Hypertriglyceridemia and cardiovascular risk* 67

*Management of hypertriglyceridemia 68*
*Pharmacotherapy for hypertriglyceridemia 68*
*Pharmacokinetics 69*
*Clinical studies 69*

**13. Beta-blockers and Coronary Artery Disease: Status 2014 ..... 72**
PP Mohanan

*Anti-ischemic effects of beta-blockers 72*
*Beta-blockers in acute coronary syndrome: ST-segment elevation in myocardial infarction 72*
*Secondary prevention 73*
*Stable coronary artery disease 74*
*Reduction of atherothrombosis for continued health registry and questions about the cardioprotective efficacy of beta-blockers? 75*

**14. Statin Guidelines: Controversies to Consensus (What to Follow in 2014?) ..... 77**
Santanu Guha, Siddhartha Mani, Suchit Majumdar

*Scope of the guidelines 77*
*Whom to treat? 77*
*What to treat? 78*
*How to treat? 78*

**15. ARBs and CVD Protection: New Dimension 2014 ..... 81**
Vijay K Trehan, Ankit Bansal

*Hypertension 82*
*Heart failure 82*
*Myocardial infarction 82*
*Renal function 82*
*Diabetes 82*
*Stroke 83*
*Left ventricular hypertrophy 83*
*Atrial fibrillation 83*

**16. Amiodarone and Cardiovascular Disease Protection: Clinical Implications 2014 ..... 85**
Mrinal Kanti Das

*Molecular structure 85*
*Electrophysiological properties 86*
*Dosing 86*
*Metabolism 86*
*Indications 87*
*Evidences with some key trials with the drug 88*
*Adverse effects of amiodarone 88*

**17. Gaps and Challenges in Antiplatelet Therapy: Indian Perspective ..... 90**
Balaji Pakshirajan, Ajit Mullasari

*Antiplatelet agents 90*
*Antiplatelet drugs under development 93*
*Guidelines for antiplatelet therapy 93*
*Current choice of antiplatelet therapy: Indian perspective 93*

**18. Triple Antiplatelet Therapy in Acute Coronary Syndrome in 2014 ..... 97**
Rajeev Lochan

*Antiplatelet agents 97*

**19. Drug–Drug Interactions in Cardiology ..... 103**
S Nagendra Boopathy, Ambuj Roy
*Incidence and prevalence 103*
*Classification 103*
*Drug–drug interactions in patients with heart failure 103*
*Coronary artery disease 105*
*Arrhythmia 106*
*Hypertension 107*
*Prosthetic heart valve 107*
*Herbal interactions 107*
*Drug interactions identification software 107*

**20. Pharmacoinvasive Strategy in the Treatment of STEMI ..... 109**
Tiny Nair
*Evolution of stemi management 109*
*Mechanical reperfusion versus thrombolysis 109*
*Problems of delay in therapy 110*
*Early thrombolysis with fibrin-specific agents 110*
*Problems with thrombolytic therapy 110*
*Combined approach of reperfusion: can we avoid the delay? 110*
*Pharmacoinvasive strategy 111*
*The future: time delay between thrombolysis and PCI in pharmacoinvasive treatment 112*

**21. Post-PTCA and Post-CABG Care: What is New in 2014? ..... 114**
Satyendra Tewari, Ashok Kumar
*Care of post-PTCA patient 114*
*Care of post-CABG patient 117*

**22. Acute Coronary Syndrome Management Strategies: Recent Advances 2014 ..... 119**
Satyajeet N Suryawanshi, Shirish (MS) Hiremath
*Improved level of care for ST-segment elevation myocardial infarction 119*
*Recent advances in medical therapy for acute coronary syndrome—antiplatelet therapy 120*

**SECTION 2: CORONARY ARTERY DISEASE**

**23. Genetics and Coronary Artery Disease—Challenges ..... 127**
Soumitra Kumar, Soumen Bhat
*Genetics and CAD 127*
*Genome wide association studies and CAD 127*
*Utility in clinical practice 129*
*What is the role of gene therapy? 129*

**24. Coronary Artery Disease: Risk Factor Stratification ..... 131**
Geevar Zachariah
*Who should go for coronary artery disease risk stratification? 131*
*Who need not to go for risk stratification? 131*
*Risk stratification models 131*
*Limitations of current risk stratification models 134*

**25. Vitamin D and Cardiovascular Disease ..... 136**
Sunil Modi, Arif Wahab
*Vitamin D: physiology and basics 136*
*Risk factors 137*

*Association of vitamin D and cardiovascular disease 137*
*Treatment of vitamin D deficiency 139*
*Vitamin D and cardiovascular disease: does it really matter so much? 139*

**26. Tobacco and Heart ..... 141**
Ishita Rawal, Ajay S Vamadevan, Dorairaj Prabhakaran

*Prevalence and impact of tobacco use 141*
*Pathophysiology: tobacco and heart disease 141*
*Risk of heart disease 142*
*Benefits of tobacco cessation 144*
*Tobacco cessation interventions 145*
*Tobacco regulation 145*
*Challenges to tobacco control 146*

**27. Stress and Heart ..... 150**
Satish Kumar Gupta

*Historical perspectives 150*
*What is stress? 151*
*Model of stress response 151*
*Acute versus chronic stress 151*
*Brain–heart connection 152*
*Natural history of stress-induced heart disease 152*
*Pathophysiological mechanism of stress and CAD 154*
*Stress cardiomyopathy 155*
*Spirituality, stress, and heart health 156*
*Therapeutic implications 157*
*Our experience 157*
*Future research and perspectives 158*

**28. Role of Psychosocial Factors and Relaxation Techniques in the Etiology and Prevention of Cardiovascular Diseases ..... 160**
Priya Chockalingam, Anand Chockalingam, V Chockalingam

*Psychosocial factors and cardiovascular diseases 160*
*Ideal cardiovascular health and behavioral cardiology 161*
*Positive psychological well-being and relaxation techniques 161*

**29. Trans Fat and Cardiovascular Disease ..... 165**
SKD Bhardwaj

*What are trans fats? 165*
*Source of trans fats 165*
*How do trans fats affect you? 165*
*Result of study on trans fats 165*
*Trans fats and coronary heart disease 165*
*Systemic inflammation 166*
*Potential molecule mechanism 166*
*How to reduce artificial trans fat? 166*
*American Heart Association/American College of Cardiology recommendation 166*
*How much trans fat can I eat a day? 166*

**30. Homocysteine and Coronary Artery Disease ..... 168**
GS Sainani

*Biochemistry of homocysteine 168*
*Estimation of total homocysteine levels 169*

*Relation between hyperhomocysteinemia and endothelial cell dysfunction 169*
*Treatment of hyperhomocysteinemia 170*

**31. State-of-the-art Review on Metabolic Syndrome, Diabetes, and Cardiovascular Disease ..... 173**
Prakash Deedwania

*Background 173*
*Prevalence 173*
*Pathophysiology of cardiometabolic syndrome 174*
*Clinical implications 174*
*Therapy 174*
*Progression from metabolic syndrome to diabetes and cardiovascular disease 177*
*Management of individual risk factors 178*

**32. Vulnerable Plaque in a Vulnerable Patient: How to Manage? ..... 184**
Varun Gupta, Sandeep Singh

*Mechanisms converting a stable plaque to a VP 184*
*Identifying the VP 185*
*Identifying the vulnerable patient 185*
*Treatment strategies 185*

**33. Microvascular CAD: Management Issues 2014 ..... 189**
Manish Aggarwal

*History 189*
*Classification 189*
*Risk factors for coronary microvascular dysfunction 189*
*Pathophysiology 190*
*Management 190*

**34. Hormone Replacement Therapy and Heart ..... 193**
Vinod Sharma, Sibaji Phaujdar, Ruchi Sharma

*Age-related effects of hormone replacement therapy 194*

**35. Lifestyle and Coronary Artery Disease ..... 196**
SC Manchanda, Kushal Madan

*What is lifestyle? 196*
*Role of yoga 198*
*Evidence for lifestyle modifications 198*

**36. Using Health Behavior Change Theory to Guide Health Promotion to Prevent Noncommunicable Diseases in India ..... 201**
Mahati Chittem, Sriramya Vemulakonda, Ramesh B Byrapaneni

*Health behavior theories 201*
*Using health behavior theory to guide health promotion in preventing noncommunicable diseases 203*

**SECTION 3: HEART AND NUTRITION**

**37. Nutrition and Heart ..... 207**
Adarsh Kumar, Harharpreet Kaur, Ankita Attri

*How nutrition affects the cardiovascular risk 207*
*General dietary recommendations 209*

**38. CoQ10 and CVD Risk Reduction 2014 ..... 211**
HK Chopra, Adarsh Kumar
*Potential clinical uses of CoQ10 in CVD risk reduction 211*

**39. CoQ10 in CHF and CAD: Potentials and Challenges Ahead ..... 214**
Adarsh Kumar, Harharpreet Kaur, Ankita Attri
*Role in congestive heart failure 214*
*Role of CoQ10 in coronary artery disease 215*

**40. Edible Oils in Cardiovascular Disease Protection ..... 218**
Shashank Joshi
*Fats and oils: basics 218*
*Edible oil industry: global scenario 220*
*Edible oil industry: Indian perspective 220*
*Free radicals: health paradox 221*
*Antioxidants: in human health 222*
*Edible oils: antioxidants 222*

**41. Management of Obesity: By Optimizing Nutrition ..... 224**
Sonia Arora, Vitull K Gupta, Meghna Gupta
*Weight control is a journey, not a destination 224*
*What is obesity? 224*
*Methods to calculate obesity 224*
*Pathophysiology of obesity 225*
*Causes of obesity epidemic in India 225*
*How to manage obesity 225*
*Drug therapy 228*
*Weight loss surgery 228*

**SECTION 4: CARDIAC INVESTIGATION**

**42. Coronary Artery Disease and Biomarkers ..... 233**
Satyavan Sharma, Satish Kumar, Suresh Kolekar
*Classes of cardiac biomarkers 233*
*Role of cardiac biomarkers in CAD 234*

**43. Electrocardiogram: Pitfalls in Diagnosis and Artifacts ..... 237**
Amit Vora, Samhita Kulkarni
*Electrocardiogram: pitfalls in diagnosis 237*
*Wrong lead placement 239*
*Electrocardiogram artifacts 240*

**44. Echocardiography: Beginning, Present, and Future ..... 244**
Arka Chatterjee, Navin C Nanda
*1950–1990 244*
*1990–Present 246*
*Future 251*

**45. Stress Echocardiography and Coronary Artery Disease ..... 255**
Nitin Burkule
*Why do we need stress echo? 255*
*Pathophysiology of ischemia and regional wall motion abnormality 255*

**46. Stress Myocardial Perfusion Imaging ..... 263**
Johann Christopher, Raghu Krishnaswamy

*Choice of test modality 263*
*Technical issues 266*
*Exercise myocardial perfusion imaging for diagnosis 266*
*Exercise myocardial perfusion imaging for prognosis 267*
*Exercise myocardial perfusion imaging for choice of therapy 269*

**47. LV Diastolic Function Evaluation: What is Practical? ..... 271**
SK Parashar

*Hemodynamic concepts of diastole 271*
*What is diastolic dysfunction 272*
*Echocardiographic techniques to evaluate diastolic dysfunction 272*
*Hemodynamic determinants of Doppler parameters 275*
*Types of diastolic dysfunction 275*
*Basic rule of diastolic dysfunction 276*
*Diagnosis of various grades of diastolic dysfunction 276*
*Assessment of diastolic dysfunction in atrial fibrillation 278*
*Clinical applications of diastolic dysfunction 279*
*Suggested guidelines for subjective evaluation of filling, pressure (Nagueh et al., 1997) 280*
*Diastolic stress echocardiography 280*
*New diastolic indices 281*

**48. Echocardiographic Evaluation in Elderly: What is New? ..... 283**
George Thomas

*Cardiac changes in the elderly 283*
*Characteristics of illness in elderly patients 284*
*Problems of echocardiographic acquisition in elderly patients 284*
*Common echocardiographic abnormalities in the elderly patients 284*
*Echocardiographic diagnosis in the elderly patients 286*

**49. Myocardial Contrast Echocardiography: Usefulness and Pitfalls ..... 288**
Asrar Ahmed, Gurunathan Sothinathan, Jatinder Singh Pabla, Roxy Senior

*Pathophysiologic basis of MCE 288*
*Role of MCE in clinical practice 288*
*Pitfalls 292*

**50. Echocardiography and Post-MI Complications ..... 295**
P Krishnam Raju, K Raghu, Chandramukhi

*Complications of MI 295*
*Cardiac rupture 296*
*Mitral regurgitation 299*
*Atrial infarction 302*
*Diastolic dysfunction 302*

**51. Three-dimensional Echocardiography: Is it Superior to Two-dimensional Echocardiography for Valvular Heart Disease ..... 305**
Sameer Shrivastava, Vinay Kumar Sharma

*Acquisition of 3D data set: technical considerations 305*
*Advantages of 3DE in evaluation of mitral valve disease 306*
*Assessment of aortic valve 307*
*Assessment of pulmonary valve 307*

*Assessment of tricuspid valve 308*
*Utility of 3D TEE during surgical and interventional procedures 308*
*Timing of surgery: the assessment of LV function 308*

**52. Strain and Strain Rate Imaging: Clinical Implications 2014 ..... 310**
Naveen Garg, KK Kapur

*What is strain and strain rate? 311*
*Types of strains 311*
*Myocardial architecture 311*
*Rotational mechanics 312*
*Procedure and technique for performing strain imaging 313*
*Clinical applications of speckle tracking echocardiography 313*
*Myocardial diseases 314*
*Hypertension 314*
*Hypertrophic cardiomyopathy 314*
*Diabetes 314*
*Athlete's heart 314*
*Coronary artery disease 315*
*Heart failure and dyssynchrony 315*
*Dilated cardiomyopathy 315*
*Stress cardiomyopathy 316*
*Pericardial diseases and restrictive cardiomyopathy 316*
*Valvular heart disease 316*
*Congenital heart disease 316*
*Heart transplant and rejection 316*
*Chemotherapy 316*
*Left atrial strains 316*
*RA strain 317*
*Limitations 317*

**53. Need of Cardiac Evaluation in Obesity ..... 322**
CP Roy, Mitendra Singh Yadav

*Cardiovascular pathophysiology/hemodynamics 322*
*Clinical assessment of adult obesity* 324
*Identifying the high-risk obese patient 326*
*Approaching obesity as a chronic disease 326*

**SECTION 5: ACUTE MYOCARDIAL INFARCTION**

**54. Management of Acute Myocardial Infarction in 2014 ..... 331**
Neeraj Parakh, VK Bahl

*Prehospital management 331*
*Reperfusion therapy 332*
*Adjunct anticoagulant therapy with thrombolysis 334*
*Stem cell therapy 335*
*Indian scenario 336*
*Future directions 336*

**55. Thrombolysis in Acute Myocardial Infarction: Which Agent is the Right Choice? ..... 339**
SS Iyengar

*Thrombolytic agents 339*

**56. Primary Angioplasty in 2014 ..... 342**
Nagendra S Chouhan, Praveen Chandra

*Status of primary PCI in india 343*
*Pharmacoinvasive approach to primary PCI 344*
*Newer drugs in AMI armamentarium 344*
*Newer devices in AMI armamentarium 346*

**57. Thrombus Aspiration During Primary Percutaneous Coronary Angioplasty ..... 351**
Dev B Pahlajani

**58. Cardiogenic Shock in Acute Myocardial Infarction ..... 354**
Ashwin B Mehta, Rahul Chhabria

*Definition of cardiogenic shock 354*
*Incidence of cardiogenic shock 355*
*Pathophysiology of cardiogenic shock 355*
*Diagnosis 355*
*Management of cardiogenic shock in AMI 355*
*Treatment of cardiogenic shock 356*

**59. Post-MI: Risk Stratification and Cardiac Rehabilitation ..... 359**
Kushal Madan, JPS Sawhney

*Post-MI: risk stratification 359*
*Post-MI: cardiac rehabilitation 362*

**60. Revascularization in Acute Myocardial Infarction Patients 24 Hours after Thrombolysis ..... 367**
GR Kane, Piyush Goenka

*PAMI: best option out there! 367*
*Rescue PCI 367*
*Facilitated PCI 367*
*Delayed routine and selective PCI 368*
*PCI of an infarct artery versus non-infarct artery 368*
*Stent in PCI 369*
*Antiplatelet therapy to support delayed PCI after fibrinolysis 369*
*Anticoagulant therapy to support delayed PCI after fibrinolysis 369*
*Anticoagulant therapy to support primary PCI after fibrinolysis 369*
*CABG in patients with STEMI 370*
*Pharmacological therapy 370*

**61. Thrombolytic Therapy in STEMI Interventions ..... 372**
Mehta S, Oliveros E, Reynbakh O, Kostela J, Ossa MM, Zhang T, Botelho R, Rodriguez D, Botero M, Thomas J, Para D

*Guidelines for reperfusion therapy in acute myocardial infarction 372*
*Benefits of choosing early reperfusion therapy 373*
*Data supporting the use of thrombolytics in STEMI 373*
*Other relevant trials 376*
*Thrombolytic therapy for AMI management in India 377*
*Indigenous tenecteplase 378*
*Is there room for thrombolytic therapy in the era of PPCI? 379*
*Future perspectives 380*

## SECTION 6: CORONARY INTERVENTION

**62. Chronic Total Occlusion (CTO): Strategies and Wiring Techniques ..... 385**
Sudhir S Shetkar, Sandeep Singh, Sundeep Mishra

*Guidewires for chronic total occlusions 385*
*Role of microcatheters in CTO PCI 386*
*Strategies and wiring techniques 386*
*Advance wiring techniques 387*
*Advance wiring techniques for retrograde approach 389*

**63. Chronic Total Occlusion: Management Strategies 2014 ..... 392**
Pankaj Jariwala, K Sarat Chandra

*Definition, incidence, and presentation 392*
*Success rates of chronic total occlusion intervention 394*
*Challenges of chronic total occlusion lesions 394*
*Imaging for chronic total occlusions 395*
*Algorithm for crossing chronic total occlusions 395*
*Guidewire selection and utilization 396*
*Approach to the CTO 396*
*Complications associated with CTO angioplasty 399*
*Novel crossing and re-entry system in coronary chronic total occlusions 399*
*Drug-eluting stent implantation for chronic total occlusions 400*

**64. Radial Angioplasty: Tips and Tricks ..... 402**
Sanjay Chugh, Yashasvi Chugh

*Overcoming the challenges 402*

**65. Guidelines for PCI 2014: Training for Percutaneous Coronary Intervention Appropriateness, Indications and Directions ..... 412**
Anil Dhall, Sanjat S Chiwane

*Competence and training standards 413*
*Scores and risk stratification 414*
*Decision making and patient information 414*
*Timing of angiography and intervention in NSTEMI-USA group 415*
*Timing of angiography and intervention in STEMI group 415*
*Timing of angiography and intervention in chronic stable angina 416*
*PCI in special groups 417*
*Drug-eluting stents 418*
*Drug-eluting balloons 418*
*Bioresorbable vascular scaffolds 419*
*Adjunctive invasive diagnostic tools 419*

**66. Complex Coronary Angioplasty Procedure: Tips and Tricks ..... 423**
Viveka Kumar, Rajendra Kumar Agarwal

*Bifurcation lesions 424*
*Fibrocalcific and undilatable lesions 425*
*Chronic total occlusion 425*
*ULMCA stenoses 425*
*Thrombotic lesions 426*
*Saphenous vein grafts 426*
*Key points 426*

**67. Drug-eluting Stents: Differing Platforms and Outcome ..... 428**
Shuvanan Ray, David Rozario

*Drug-eluting stents 428*
*Drug reservoir technology 428*
*Antiproliferative agents 428*
*Limus analogues 429*
*Drug-eluting stents platform 429*
*Newer generation drug-eluting stents with durable polymer 430*
*Biodegradable polymers 431*
*Polymer-free drug-eluting stents 432*
*Drug-eluting stents with durable polymers versus biodegradable polymers versus polymer-free drug-eluting stents 433*
*Dual drug-eluting polymer-free stent versus durable polymer sirolimus-eluting stents versus durable polymer zotarolimus-eluting stent 433*
*Platinum-chromium drug-eluting stents 433*
*Bioresorbable vascular scaffolds 434*

**68. Role of Rotational Atherectomy in Percutaneous Coronary Interventions ..... 436**
Prashant T Upasani, Purshotam Lal

*Mechanism 436*
*Equipment 436*
*Procedure 437*
*Lesion selection 437*
*Indications 437*
*Outcomes 438*
*Clinical results 439*
*Rationale for use 439*

**69. Can We Predict Stent Thrombosis and So Prevent It? ..... 442**
Kajal Ganguly, Pradip Ghoshal, Santanu De, Arindam Basu

*What is stent thrombosis? 442*
*Burden of stent thrombosis 442*
*Prediction of stent thrombosis 443*
*Prevention of stent thrombosis 444*

**70. Biovascular Scaffolds: New Dimension 2014 ..... 446**
PC Rath, Sundar Chidambaram, B Dikshit

*Contemporary bioresorbable scaffolds and ongoing clinical trials 446*

**71. Indigenous Stents: Examining the Clinical Data on New Technologies ..... 450**
Sreenivas Kumar Arramraju, Hariram Vuppaladadhiam

*Indigenous stents: historical perspective 450*
*Indigenous bare metal stents 451*
*Indigenous bare metal stents (with limited clinical data) 451*
*Drug-eluting stents 451*
*Peripheral 458*
*Future perspectives 458*

**72. Hybrid Coronary Revascularization: An Integrated "Best of Both Worlds" Approach to Revascularization ..... 461**
Harinder K Bali, Hiteshi KC Chauhan

*Introduction—the "hybridized wave" of the future? 461*
*Evolution of HCR 462*

*Indications for HCR 463*
*Relative contraindications 463*
*Technical aspects of HCR 464*
*"Sequencing" HCR 464*
*Rationale for HCR 464*
*Factors against HCR 464*
*Current guidelines 464*
*HCR—Indian scenario 465*

**73. Management of Coronary Stent Restenosis: New Dimensions ..... 468**
Pravin K Goel, Jugal Sharma

*Management of coronary stent restenosis: new dimensions 468*
*Definition, classification and mechanisms 468*
*Clinical presentation 469*
*Clinical approach and management 470*

**74. Saphenous Vein Grafts Intervention: Challenges 2014 ..... 474**
Alok Mazumdar

*Natural history of vein grafts 474*
*Pathophysiology of saphenous vein graft disease 474*
*Percutaneous treatment (PCI) of saphenous vein graft obstructions 475*
*Value of intravascular ultrasound in vein graft interventions 475*
*Strategies to prevent no-reflow in Saphenous vein graft interventions 475*
*The ACC/AHA indications for post-CABG-SVG Disease interventions 477*
*Practical approaches to SVG PCI 477*

**SECTION 7: PERIPHERAL VASCULAR INTERVENTION**

**75. Carotid Evaluation: How to Do, 2014 ..... 483**
SS Mishra, BR Mishra, SN Routray, PK Pradhan, TK Mishra

*Extracranial carotid atherosclerosis 483*
*Clinical examination 485*
*Imaging 485*
*Approach to imaging 486*

**76. Carotid Intervention: Current Status and Future Direction ..... 490**
Rajneesh Kapoor, Peeyush Kumar Roy, Himanshu Dabral

*Natural history of carotid artery disease 490*
*Benefits of carotid revascularization 491*
*Carotid artery stenting: clinical evidence 491*
*Carotid artery stenting: the procedural technique 492*
*Complications 494*
*Future prospective 494*

**77. Aortic Evaluation and Interventions: Status 2014 ..... 496**
NN Khanna, Suparna Rao

*Evaluation 496*
*Coarctation of aorta 496*
*Aortic aneurysm 498*
*Thoracic aortic aneurysm 500*
*Abdominal aortic aneurysm 501*
*Aortic dissection 504*

*Takayasu arteritis 505*
*Atherosclerosis of aorta 510*

**78. Peripheral Vascular Evaluation and Intervention ..... 513**
CM Nagesh, BC Srinivas, Ashish Gupta, Babu Reddy

*Epidemiology 513*
*Diagnosis and evaluation 513*
*Therapeutic strategies 516*
*Revascularization 516*
*Endovascular treatment 516*
*Acute limb ischemia 520*

**79. Chronic Lower Limb Ischemia: Management Strategies ..... 523**
Amit Kumar, Atul Mathur

*Epidemiology of PAD 523*
*Natural history of PAD 523*
*Clinical presentation 523*
*Imaging studies 524*
*Management of lower extremity PAD 524*
*Acute limb ischemia 525*

**80. Erectile Dysfunction and Coronary Artery Disease ..... 529**
Aditya Kapoor

*Clinical assessment of erectile dysfunction 529*
*Coprevalence with cardiovascular disease 529*
*Association with severity of coronary artery disease 530*
*Is erectile dysfunction a greater predictor of cardiovascular disease in younger males? 530*
*Role of penile Doppler test 530*
*Does erectile dysfunction predict adverse cardiovascular events and cardiovascular disease mortality? 530*
*Is erectile dysfunction also present in those without manifest coronary artery disease 531*
*Pathophysiology and the role of endothelial dysfunction 531*
*Correlation with clinical mode of presentation of coronary artery disease 531*
*Erectile dysfunction often precedes coronary artery disease 532*
*Should erectile dysfunction patients be routinely screened for coronary artery disease? 532*
*Management of the erectile dysfunction patient with cardiovascular disease 532*
*Risk of sexual activity 533*

**SECTION 8: HEART FAILURE**

**81. Biomarkers in Heart Failure: Newer Horizon ..... 537**
Amal Kumar Banerjee

*Natriuretic peptides 538*
*Biomarkers of myocardial injury: cardiac troponin T or I 538*
*Extracellular matrix markers 539*
*Aldosterone 539*
*Markers of inflammation 539*
*Adrenomedullin 539*
*Copeptin 539*
*Neutrophil gelatinase-associated lipocalin 539*
*Kidney injury molecule-1 539*
*Quiescin Q6 539*
*High-sensitivity ST2 539*

*Galectin-3 540*
*Multimarker approaches 540*

**82. Echo and Diastolic Heart Failure ..... 542**
Satish C Govind, Harsha Basappa
*Pathophysiology 542*
*Causes 542*
*Diagnosis 543*
*Echocardiography 543*

**83. BNP Evaluation Guidelines in CHF ..... 546**
Jabir A, Jo Joseph, Rony Mathew Kadavil
*Natriuretic peptides 546*
*BNP metabolism 546*
*NT-proBNP versus BNP 547*
*Causes of NP elevation 547*
*NP levels lower than expected 547*
*Clinical utility of BNP 547*
*BNP in differentiating dyspnea of cardiac origin 547*
*BNP consensus algorithm and optimal NT-proBNP cutoff points 547*
*Natriuretic peptides in the prognosis of heart failure 547*
*Monitoring therapy and optimizing outcomes 547*
*Caveats in the use of NPS 548*

**84. Anemia in Chronic Heart Failure ..... 551**
Vidyut Jain, Avani Jain
*Etiology of anemia in chronic heart failure 551*
*Pathophysiology of anemia in chronic heart failure 552*
*Treatment of anemia in chronic heart failure 553*

**85. When to Revascularize in Heart Failure? ..... 557**
G Sengottuvelu, R Ravindran, Dattagupta Aditi
*Definition of ischemic LV dysfunction 557*
*Mechanism of ischemic LV dysfunction 557*
*Assessment of viability 558*
*Evidence for revascularization in heart failure 559*

**86. Acute Decompensated Heart Failure ..... 561**
Mohit D Gupta, MP Girish, Jyoti Prakash Lal Karn
*Diagnosis 561*
*Treatment strategies of ADHF 562*
*Pharmacologic agents in development for ADHF 566*

**87. Managing Comorbidities in Heart Failure ..... 569**
Nakul Sinha
*Diabetes 570*
*Hypertension 570*
*Anemia 570*
*Fatigue/generalized weakness 571*

**88. CHF and CKD—Double Jeopardy: How to Manage? ..... 573**
UC Samal, Anand Santosh
*Preamble 573*

*Management* 573
*Pathophysiology* 574

**89. Heart Failure Management in Women: Is it Different?** ..... **577**
Chetan P Shah
*Epidemiology of heart failure* 577
*Etiology* 578
*Prognosis* 578
*Pharmacologic interventions in management of women with heart failure* 578
*Nonpharmacologic interventions* 580

**90. Left Ventricular Assist Devices: New Frontiers 2014** ..... **581**
Vishal Rastogi, Bhumika S Anand
*Surgicaly implanted VAD* 581
*Pre-procedural planning* 582
*Percutaneous left ventricular assist devices* 583

**SECTION 9: HYPERTENSION**

**91. Approach to a Newly Diagnosed Hypertensive** ..... **589**
Dhiman Kahali, Paramita Banerjee
*Definition* 589
*Diagnosis and initial evaluation* 590
*Evaluation of target organ damage* 590
*Secondary hypertension* 590
*General approach to patient* 591
*Specific strategies and approach for patient in different age groups* 591
*Approach to hypertension treatment* 593

**92. Ambulatory BP Monitoring: Is It Really Essential?** ..... **595**
George Koshy A, Sajan Ahmad Z
*Ambulatory BP monitoring—why?* 595
*Ambulatory BP monitoring—how is it done?* 595
*Ambulatory BP monitoring—major roles* 596
*Ambulatory BP monitoring—additional roles* 597
*Ambulatory BP monitoring targets in hypertension management* 598
*Ambulatory BP monitoring—logistic issues* 598
*Ambulatory BP monitoring—what the guidelines say* 599

**93. Cardiovascular Risk in Hypertension: How to Manage It?** ..... **602**
A Banerji, S Sengupta
*Definitions* 602
*Epidemiology of cardiovascular disease and hypertension* 602
*Indian epidemiological perspective* 603
*Markers of increased cardiovascular risk in hypertension* 603
*Management of hypertension* 603

**94. Role of Echocardiography in Hypertension** ..... **607**
Hardeep Kaur Grewal, Manish Bansal, Ravi R Kasliwal
*Pathophysiology of hypertension* 607
*Role of echocardiography in hypertension* 607

**95. Nonpharmacological Management of Hypertension 2014 ..... 617**
Pramod Joshi, Ashish Jai Kishan, Suman Bhandari
*Recommended lifestyle modifications 617*

**96. Resistant Hypertension: Clinical Evaluation and Management ..... 622**
Mohsin Wali, Sanjeev Sharma, C Venkata S Ram
*Pseudoresistance to therapy 623*
*Pathobiology of resistant hypertension 623*
*Renal artery stenosis 624*
*Chronic kidney disease 624*
*Primary aldosteronism 624*
*Pheochromocytoma 624*
*Other endocrine disorders 624*
*Obstructive sleep apnea syndrome 625*
*Non-drug therapy 625*
*Correction of secondary causes 625*
*Pharmacological options and principles to treat resistant hypertension 626*
*Maximize adherence 626*
*Antihypertensive drug dosing 626*
*Adjusting the diuretic therapy 626*
*RAAS blockers 626*
*Calcium channel blockers 626*
*Other antihypertensive drugs 627*
*Mechanical device-based therapy 627*
*Unanswered questions 627*

**97. Indian Practical Guidelines for Management of Hypertension ..... 629**
Rakendra Singh, Abhishek Goyal, Gurpreet S Wander
*The third Indian guidelines on hypertension (IGH)-III 629*
*Epidemiology 629*
*Definition and classification 629*
*Measurement of blood pressure 630*
*Management of hypertension 631*
*Secondary hypertension 633*
*Hypertension in special situations 633*
*What is new in third Indian hypertension guidelines 633*

**98. Choosing the Right Drug for Your Hypertensive Patient: A Look at Comorbidities ..... 635**
Narender O Bansal, Sandesh Prabhu
*Chronic kidney disease 635*
*Elderly hypertensives 635*
*People with coronary artery disease 636*
*People with congestive heart failure 636*
*People with diabetes 637*
*People with high cholesterol 637*
*People with respiratory disease 637*
*People with gout and hyperuricemia 637*
*Liver diseases 638*
*Hypertension in pregnancy 638*

*Antihypertensive in breastfeeding 638*
*Obstructive sleep apnea syndrome 638*
*Obesity 639*
*Metabolic syndrome 639*

**99. Renal Denervation: Present Status and Future Direction ..... 640**
Arup Dasbiswas, Debasri Dasbiswas
*Resistant hypertension 641*
*Renal denervation quick facts 641*

**100. Recent Advances in Hypertension Management for Cardiovascular Disease Prevention ..... 646**
Rajeev Gupta
*Hypertension as cardiovascular risk factor 647*
*Primordial prevention and lifestyle changes 647*
*Pharmacotherapy and interventions 649*
*Health systems approach 651*

**101. Hypertension Paradoxes ..... 654**
Jagdish Hiremath, Kaushik Sheth
*Effectiveness of therapy 654*
*Step care approach 654*
*Combination therapy 654*

**102. Hypertension Management Strategy in Renal Artery Stenosis ..... 656**
TK Mishra
*Scenario 656*
*Renovascular syndromes with RAS 656*
*Functional classification of atherosclerotic RAS 656*
*Pathophysiology of renovascular hypertension 656*
*Hypertension in RAS 657*
*Medical therapy of renovascular hypertension 657*
*RAS and refractory hypertension 658*
*Revascularization 658*
*Endovascular renal angioplasty and stenting 658*
*Lessons learnt 659*
*Cause of no drastic benefit of revascularization in ARAS 660*
*Surgical modality 660*

**103. Central Aortic Blood Pressure as a Prognostic Marker in Hypertension ..... 661**
C Venkata S Ram
*Central aortic pressure and arterial stiffness in cardiovascular disease 661*
*Central aortic pressure and arterial stiffness as predictors of cardiovascular risk in outcome studies 662*
*Assessment of CAP and arterial stiffness 662*
*Therapeutic effect of antihypertensive drugs based on central and peripheral BP levels 663*

**SECTION 10: VALVULAR HEART DISEASE**

**104. TAVR Present Status and Challenges Ahead ..... 669**
Vijay Kumar, Ashok Seth
*Current Status of TAVR 669*
*TAVR technology today and the challenges ahead 670*

*Prosthesis durability 671*
*Valve in valve TAVR 672*
*Imaging in TAVR 672*
*Vascular access site issues 674*
*Other ongoing issues with TAVR and the Challenges 675*
*Stroke 676*

**105. Percutaneous Mitral Valvuloplasty: Tips and Tricks ..... 681**
KC Goswami, Sunil Kr Verma

*Clinical profile of the patient 681*
*Echocardiography 681*
*Transseptal catheterization 682*
*Preparation of balloon 683*
*Crossing the mitral valve 683*
*Safe and Effective balloon dilation 684*
*Avoiding complications specially Mitral Regurgitation 684*

**106. Rheumatic Heart Disease: Epidemiology and Management ..... 687**
Arati Dave Lalchandani, Manoj Godara, Navin Mathiyalagan

*Epidemiological factors 687*
*Epidemiology 687*
*Management 688*

**107. Echocardiography in Rheumatic Heart Disease ..... 691**
IB Vijayalakshmi

*Background 691*
*Transthoracic echocardiography 691*
*Echocardiography versus clinical examination 691*
*Accurate diagnosis is eluding clinicians 692*
*Echocardiography features of carditis 692*
*Is echocardiography superior in the diagnosis of carditis? 693*
*Integrative approach to assessment of severity of mitral regurgitation 693*

**108. Percutaneous Valve Repair/Replacement: Status 2014 ..... 697**
Sunil Vanzara, Ramakanta Panda

*Transcatheter aortic valve replacement 697*
*Indications 697*
*Technique 698*
*Technical considerations 698*
*Results 699*
*Partner trial 700*
*Complications 701*
*Future 702*
*Transcatheter mitral valve repair 704*
*Valve-in-valve for failing bioprostheses 704*

**109. Prosthetic Valve Thrombosis: Management Strategies ..... 706**
G Karthikeyan

*Clinical presentation 706*
*Diagnosis 706*
*Treatment 707*
*Key points 709*

**110. Echo Navigation: A Glimpse into the Future ..... 711**
Ashok K Omar, Nishant Kumar
*Newer catheter-based approaches 711*

**111. Complex Issues in Aortic Valve Diseases ..... 716**
Hardeep Kaur Grewal, Manish Bansal, Ravi R Kasliwal
*Aortic stenosis 716*
*Aortic regurgitation 721*
*Bicuspid aortic valve in absence of severe AS or AR 721*

**SECTION 11: CARDIOMYOPATHY**

**112. Management of Dilated Cardiomyopathy ..... 727**
Ajay Behl, KK Talwar
*Evaluation 727*
*Treatment 728*

**113. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Current Status ..... 730**
I Sathyamurthy, K Jayanthi
*Hypertrophic cardiomyopathy 730*
*Treatment options 730*
*Procedure of alcohol septal ablation 730*
*Mechanism of treatment efficacy 731*
*Adverse events 731*
*Case selection for alcohol septal ablation 731*
*Harm 731*
*Trials of alcohol septal ablation 731*
*Future novelties 732*

**114. Genetic Evaluation in Hypertrophic Cardiomyopathy ..... 733**
Ajay Bahl
*What is the genetics of hypertrophic cardiomyopathy? 733*
*What are the problems in genotyping hypertrophic cardiomyopathy? 733*
*What is the significance of identified sequence variations? 734*
*What is the role of genotyping in family screening? 734*
*What are the clinical situations where screening is useful? 734*
*Does genotyping help in risk stratification? 734*
*What are the limitations of screening? 734*

**115. Restrictive Cardiomyopathy: Management Strategies ..... 736**
Harsh Wardhan, Ankur Agarwal
*Restrictive cardiomyopathy 736*
*Specific causes and their treatment 738*

**116. Peripartum Cardiomyopathy ..... 740**
SB Gupta
*Definition 740*
*Epidemiology 740*
*Nomenclature 740*
*Etiopathogenesis 741*
*Clinical features 741*
*Differential diagnosis 741*

*Diagnosis 741*
*Risk factors 742*
*Management 742*
*Prognosis 742*

**117. Stress Cardiomyopathy ..... 744**
Roopa Salwan

*Prevalence 745*
*Concepts about pathophysiology 745*
*Multivessel epicardial coronary artery spasm 745*
*Coronary microvascular impairment 745*
*Catecholamine cardiotoxicity 745*
*Patient demographics and presenting signs and symptoms 746*
*Echocardiographic findings 746*
*Echocardiography 747*
*Cardiac magnetic resonance imaging 747*
*Cardiac catheterization and angiographic findings 748*
*Systolic and diastolic dysfunction in stress cardiomyopathy 748*
*Management 750*
*Recurrence rate and prognosis 750*

**SECTION 12: DYSLIPIDEMIA AND CARDIOMETABOLISM**

**118. High Sensitivity C-reactive Protein: The Most Powerful Predictor of Occult Cardiovascular Disease in Patients of Metabolic Syndrome: A Hospital-based Study ..... 755**
HK Chopra, Pranjali Gupta, Krishna CK, KK Aggarwal, RS Sambi

*Materials and methods 755*
*Results 756*
*Discussion 759*

**119. Heart Disease and Exercise in Cold Weather ..... 762**
Peeyush Jain

*Cold weather and the heart 762*
*Mechanism of angina in cold weather 762*
*Local exposure may also be deleterious 762*
*Mouth breathing precipitates coronary spasm 763*
*Type of exercise influences the outcome 763*
*Special situations 763*
*Safety rules for exercise in cold weather 763*

**120. Exercise and CVD Protection in Metabolic Syndrome ..... 765**
Pankaj Manoria, PC Manoria

*Exercise and obesity 765*
*Exercise and insulin resistance 765*
*Exercise and glucose intolerance 766*
*Exercise and hypertension 766*
*Exercise and dyslipidemia 766*

**121. Obesity, CAD and Heart Failure: A Triple Jeopardy ..... 770**
SN Routray, Debasish Das, TK Mishra, SS Mishra

*With a very heavy heart: obesity and cardiovascular disease 770*
*Adipose tissue is an endocrine organ 770*

*Myocardial injury 770*
*Role of pericardial fat 771*
*Hemodynamic repercussion of obesity 771*
*Vascular injury 771*
*Obesity and coronary artery disease 771*
*Obesity myocardial infarction paradox 771*
*Obesity and heart failure 772*
*Effects on ventricular function 772*
*Cardiomyopathy of obesity (adipositas cordis) 772*
*The "obesity paradox" and heart failure: the story continues 772*
*Sudden cardiac death 772*
*Impact of obesity on total and cardiovascular mortality—fact or fiction 772*
*Fitness versus fatness 773*
*Management 773*

**122. Review of First Approved Dual PPAR α/γ Agonist, Saroglitazar: A Cardiologist's Perspective ..... 774**
PC Manoria, HK Chopra, Tiny Nair

*Cardiovascular diseases 774*
*Atherogenic dyslipidemia in type 2 diabetes 774*
*Modulation of PPARs and CV risk reduction 775*
*Saroglitazar—the first approved glitazar 777*

**SECTION 13: DIABETES AND HEART**

**123. CAD Preventive Strategies in Diabetes Mellitus ..... 783**
Ajay Kumar Sinha, Vikas Singh, Pramod Kumar, Anand Gopal, Sanjeev Kumar

*Optimal glycemic control in cardiovascular risk reduction 783*
*Optimal blood pressure control 784*
*Cholesterol management 784*
*Smoking cessation 785*
*Lifestyle modification 785*
*Drugs—aspirin 785*

**124. Management of Coronary Artery Disease in Diabetes Mellitus—Is It Different? ..... 787**
Asha Moorthy, Jain T Kallarakkal

*Relationship between glycemic control and cardiovascular disease 787*
*Medical management in acute coronary syndromes 787*

**125. CAD and CKD: A Double Jeopardy Management Strategies ..... 790**
ST Yavagal

*Management of CAD with CKD 790*
*Evaluation for CAD 791*
*Treatment 791*
*Prognosis 792*

**SECTION 14: PREGNANCY AND HEART**

**126: Hypertension in Pregnancy: Management Strategies ..... 795**
Vitull K Gupta, Sonia Arora, Meghna Gupta

*Definition of hypertension 795*
*Classification of hypertensive disorders of pregnancy 795*
*Management strategies 796*

**127. Management of Valvular Heart Disease in Pregnancy ..... 802**
Rajiv Bajaj
*Physiology 802*
*Antenatal care 802*
*Delivery 803*
*Mitral stenosis 803*
*Mitral regurgitation 803*
*Mitral regurgitation with mitral stenosis 803*
*Aortic stenosis 803*
*Aortic regurgitation 804*
*Right-sided valvular disease 804*
*Multivalvular disease 804*
*Endocarditis 804*
*Congestive heart failure 804*
*Arrhythmias 804*
*Surgical correction during pregnancy 804*
*Prosthetic valve management 804*
*Key points 805*

**128. Pregnancy and Pulmonary Embolism: How to Manage? ..... 806**
M Somasundaram, K Meenakshi
*Predisposing factors 806*
*Diagnosis 806*
*Differential diagnosis 808*
*Treatment 808*
*Prophylaxis 809*

**SECTION 15: TROPICAL CARDIOLOGY**

**129. Management of Takayasu's Arteritis ..... 813**
Sanjay Tyagi, Amit Mittal
*Diagnosis and assessment of disease activity 813*
*Treatment 814*
*Surgery 818*
*New perspectives and special considerations 818*

**130. Uremic Cardiomyopathy: Is it an Entity? ..... 820**
AK Kar, Ayan Kar
*Treatment 821*
*Newer treatments 821*

**SECTION 16: CARDIOPULMONARY DISEASES**

**131. Pulmonary Embolism Management Strategies 2014 ..... 825**
K Venugopal, Anjith Vupputuri
*Incidence 825*
*Risk factors 825*
*Pathophysiology 825*
*Diagnosis 826*
*Clinical presentation 826*
*Management 827*
*Role of IVC filters in pulmonary embolism 828*
*Newer oral anticoagulants (NOACS) 829*

**132. Tenecteplase and Acute Pulmonary Embolism: A Revolution ..... 830**
Lekha Adik Pathak

*Thrombolytic therapy for acute pulmonary embolism 830*
*Tenecteplase: a stronger contestant in the race of thrombolytics 831*
*Evidence base for use of tenecteplase in acute pulmonary embolism 831*

**133. Imaging in Pulmonary Hypertension ..... 834**
S Shanmugasundaram, Madhan Shanmugasundaram, B Vinodhkumar

*Why do we need imaging in suspected pulmonary hypertension patients? 834*
*Who needs pulmonary hypertension imaging tests? 835*
*What are the imaging modalities that are useful in evaluation of pulmonary hypertension? 835*
*Do we need to order all the tests in each of pulmonary hypertension suspects? 835*
*How does ECG help in diagnosis of pulmonary hypertension? 835*
*What are the findings in chest X-ray that suggest pulmonary hypertension? 835*
*How does echocardiography assist the clinician in obtaining diagnostic and prognostic information? 837*
*Invasive hemodynamics and pulmonary angiography 848*

**134. Treating Pulmonary Arterial Hypertension in 2014 ..... 852**
Abhinit Gupta, S Ramakrishnan

*Evolving classification of PAH: evolution of treatment algorithms 852*
*Targeted treatment of PAH 855*
*Prostanoids 855*
*Endothelin receptor antagonists 856*
*Phosphodiesterase-5 inhibitors 857*
*Soluble guanylate cyclase stimulators 857*
*Interventional therapies 858*

**135. Pulmonary Arterial Hypertension: Current Treatment's Success and Failure ..... 861**
Saroj Mondal, Madhumanti Panja, Priyam Mukherjee, Manotosh Panja

*Calcium channel blockers 862*
*Endothelin receptor antagonists 862*
*Prostacyclin analogs 863*
*Phosphodiesterase-5 inhibitors 863*
*Combination treatments 863*
*Pulmonary artery denervation to treat PAH 864*
*Palliative and supportive treatments for residual dyspnea in progressive PAH 864*
*Future prospects 865*

**136. Chronic Thromboembolic Pulmonary Hypertension ..... 870**
BKS Sastry

*Pathophysiology 870*
*Clinical presentation 870*
*Diagnostic work-up 871*
*Treatment 871*
*Pulmonary thromboendarterectomy—surgery for chronic thromboembolic pulmonary hypertension 872*
*Surgical results 872*
*Postoperative residual pulmonary hypertension 872*
*Postsurgical follow-up 872*
*Pulmonary arterial hypertension-specific therapies 872*
*Balloon angioplasty 873*
*Lung transplantation 873*

**137. Cardiopulmonary Resuscitation: New Dimension 2014 ..... 874**
Rony Mathew, Karthik Tummala, Jo Joseph

*Key principles in resuscitation: strengthening the links in the chain of survival 874*
*Chest compression only CPR in witnessed out-of-hospital cardiac arrest 875*
*Is cardiopulmonary resuscitation first or defibrillation first? 875*
*Devices in cardiopulmonary resuscitation 876*
*When should cardiopulmonary resuscitation be stopped? 877*
*Should we allow family member to witness cardiopulmonary resuscitation? 878*
*Should hypothermia be a part of the postcardiac arrest care? 878*

**138. Failing RV in PAH—How to Manage? ..... 879**
Vinay Jaiswal, Jivtesh Pahwa, Prafulla Kerkar

*Normal RV 879*
*Right ventricle in pulmonary arterial hypertension 879*
*Ventricular interdependence 880*
*RV failure 880*
*Echocardiography using pulse Doppler to perform MPI 883*
*Prognostic indicators in PAH 884*
*Specific drugs 885*

**139. Anticoagulants in Venous Thromboembolism ..... 890**
VS Narain, Gaurav Kumar Chaudhary

*Initial anticoagulation therapy in VTE 890*
*Prevention of Venous Thromboembolism 892*
*Future needs 892*

**SECTION 17: PACING AND ELECTROPHYSIOLOGY**

**140. Epidemiology of Sudden Cardiac Death—India versus West ..... 897**
Pushpraj Patel, B Hygriv Rao

*Epidemiological assessment of SCD 897*
*Incidence and prevalence of SCD 898*
*SCD following st elevation myocardial infarction 898*
*Inherited arrhythmia syndromes leading to SCD 899*

**141. Markers of Sudden Cardiac Death ..... 902**
Praveen Jain, Ram Babu, Tanul Jain

*Markers of sudden cardiac death 902*
*Electrocardiographic measures 903*
*Autonomic nervous system 905*
*Repolarization abnormalities 906*
*Current guidelines in management and prevention of sudden cardiac death 907*
*Challenges facing current risk stratification strategies 908*

**142. Sudden Cardiac Death: How to Prevent? ..... 909**
Ulhas Pandurangi

*Definition 909*
*Epidemiology 909*
*Risk stratification 909*
*Implantable cardioverter defibrillator 910*
*Pharmacotherapy 911*

*Radiofrequency catheter ablation 911*
*Surgical therapy 911*
*Future 911*

**143. Sudden Cardiac Death in Athletes: Is it Different? ..... 912**
BP Singh, Ravi Vishnu Prasad, Nishant Tripathy, Nirav Kumar, Pawn Kumar, Shamboo Kumar

*Causes of sudden cardiac death in athletes 912*
*Evaluation of athletes 914*
*Structural changes of heart as a result of intense training 915*
*Black athletes 915*
*Management strategies for prevention of sudden cardiac death in athletes 916*

**144. Diagnosis and Management of Syncope ..... 920**
Rabin Chakraborty

*Neurogenic control of the heart and its effects on blood pressure 920*
*Diagnostic evaluation of neurocardiogenic syncope 921*
*Syncope secondary to structural cardiac or cardiovascular disease 924*
*Unexplained syncope in patients with high risk of sudden cardiac death 926*

**145. Atrial Fibrillation: Current Management Strategies ..... 928**
Dayasagar Rao, Nishad Chitnis

*Classification 928*
*Management strategies 928*

**146. Atrial Fibrillation with Thromboembolic Stroke: Management Strategies ..... 935**
Geetha Subramanian

*Types of atrial fibrillation 935*
*Primary prevention of stroke in atrial fibrillation 936*
*Risk stratification 936*
*Assessment of bleeding risk 937*
*Antithrombotic therapy 938*
*Antiplatelet agents 938*
*Anticoagulants 938*
*Novel oral anticoagulants 938*
*Features of stroke in atrial fibrillation 939*
*Rate and rhythm control 939*
*Defibrillation 940*
*Upstream therapy 940*
*Nonpharmacologic stroke prevention 940*
*Catheter ablation for rhythm control in atrial fibrillation 941*
*Secondary prevention of stroke 941*
*Key points 941*

**147. Tilt-Table Testing: Clinical Implications and Challenges Ahead ..... 943**
K Meenakshi

*Indications 943*
*Precautions 944*
*Clinical significance and implications 944*

**148. Ventricular Tachycardia: Recent Advances ..... 946**
Aparna Jaswal, Malay Shukla

*Prognostic significance 946*
*Advances in the management of ventricular tachycardia 946*
*Surgery for ventricular arrhythmias 950*

**149. Long and Short QT Syndrome: How to Manage? ..... 953**
Subhendu Mohanty, Sameena Khalil, M Khalilullah

*Long QT syndrome 953*
*Short QT syndrome 957*

**150. Automated Blood Pressure: A Review ..... 961**
C Varun, Rakesh Yadav

*Rise of chronic diseases and cardiovascular mortality in India 961*
*Burden of hypertension in India 961*
*Oscillometric technique 962*
*How to take BP with an automated device? 963*
*Use in patients with atrial fibrillation 963*
*Validation of instruments 963*
*Use of hand and wrist devices 963*
*Detection of atrial fibrillation with automated devices 963*

**151. Which Patients may Benefit More by Giving Antihypertensive Drugs at Night? ..... 965**
RK Saran, Gaurav Kr Chaudhary

*Significance of nocturnal blood pressure 965*
*Normal circadian pattern of blood pressure 965*
*Gradation of nocturnal blood pressure dipping 965*
*Dipping status in diabetic, CKD and resistant hypertensive patients 966*
*ESH criteria for nocturnal hypertension 966*

**152. Approach to Broad QRS Tachycardia ..... 969**
SK Dwivedi

*Differential diagnosis 969*
*Clinical approach to wide complex tachycardia 969*
*Electrocardiogram approach to wide complex tachycardia 970*
*ECG algorithms for wide complex tachycardia 971*
*Limitations of morphological criteria 972*

**153. Ventricular Tachycardia in a Structurally Normal Heart ..... 974**
Ajay Naik

*Clinical presentation and evaluation 974*
*Non-life-threatening ventricular arrhythmias, typically monomorphic 974*
*Life-threatening ventricular arrhythmias (typically polymorphic) 978*

**154. Cholinergic Tachyarrhythmia: New Dimension 2014 ..... 983**
PB Jayagopal, Jain T Kallarakkal, Anoop Gopinath

*Vagal atrial fibrillation 983*
*Other forms of cholinergic arrhythmia 984*

**155. Tips and Tricks of CRT Implantation ..... 985**
Neeraj Pandit

*General guidelines for CRT implantation procedure 985*
*Cannulation of coronary sinus 986*
*Location of coronary sinus os and advancement of sheath with contrast injection 986*
*Anatomy of coronary sinus 986*

**156. Syncope and Cardiovascular Link ..... 989**
KK Sethi, Kabir Sethi, SK Chutani

*Synonyms of vasovagal syncope 989*
*Epidemiology of syncope 989*

*Classification and causes of syncope* 989
*Pathophysiological mechanisms* 990
*History and clinical examination* 992
*Investigations in vasovagal syncope* 993
*Therapeutic issues* 996
*Prognosis* 997
*Syncope and impact on quality of life* 997
*Economic issues* 998
*Driving and syncope* 998

**SECTION 18: CEREBROVASCULAR DISORDERS**

**157. Stroke in Cardiac Patients: Preventive Strategies ..... 1003**
Sandesh Prabhu, Anil Kumar

*Natural history of stroke* 1003
*Atherosclerosis and stroke prevention* 1004
*Cardioembolic strokes: atrial fibrillation* 1004
*Left ventricular thrombi as a source of cardioembolic stroke* 1005
*Atherosclerotic disease of the ascending aorta and aortic arch and risk for ischemic stroke* 1005
*Paradoxical embolism* 1005
*Hypertension and stroke* 1005
*Prevention of intracerebral hemorrhage* 1005
*Carotid endarterectomy and carotid artery stenting* 1005
*Lifestyle and stroke prevention* 1006

**158. Acute Ischemic Stroke ..... 1008**
SV Patted, Prabhu Halkatti, Ravi Solbannavar

*Epidemiology* 1008
*Pathophysiology* 1008
*Etiology of ischemic stroke* 1009
*Classification of acute ischemic stroke* 1009
*Diagnosis of ischemic stroke* 1010
*Treatment* 1011

**SECTION 19: CONGENITAL HEART DISEASE**

**159. A Clinical Approach to Common Acyanotic Congenital Heart Diseases ..... 1017**
Neeraj Awasthy, Savitri Shrivastava

*Classification of ACHD* 1017
*Pathophysiology of ACHD* 1017
*How to suspect ACHD* 1019
*Auscultation in individual ACHD* 1021
*Chest X-ray* 1023
*Electrocardiogram* 1024

**160. How to Deliver the Best Care for Patients with Congenital Heart Disease in India ..... 1028**
Anita Saxena

*Burden of the disease in India* 1028
*Current status of pediatric cardiac care in India* 1028
*Factors responsible for current state* 1029
*Strategies for delivering the best to the least affording populations of India* 1030

**161. Interventions in Common Congenital Shunt Lesions ....1033**
S Mani Ram Krishna, R Krishna Kumar

*Atrial septal defects 1033*
*Patent ductus arteriosus 1037*
*Ventricular septal defects 1040*

**162. Atrial Septal Defect in Adults: Management Approach New Dimension....1045**
Smita Mishra

*Principles of management of atrial septal defects 1045*
*Medical management 1045*
*Catheter intervention in atrial septal defect 1047*
*Surgery 1050*
*Outcome of atrial septal defect closure 1050*

**163. Eisenmenger Syndrome—An Update....1054**
Snehal Kulkarni, Prashant Bobhate

*Definition 1054*
*Epidemiology 1054*
*Classification 1054*
*Pathophysiology 1054*
*Natural history 1055*
*Clinical features 1055*
*Investigations 1056*
*Management strategy 1056*
*Future trends 1058*

**SECTION 20: CARDIAC SURGERY**

**164. Cardiac Surgery in India: Present Status and Future Challenges....1063**
N Trehan, U Dhir

*Minimally invasive surgeries 1063*
*Transcatheter valves 1063*
*Indications 1064*
*Heart failure surgery 1064*
*Robotic surgery 1064*
*Stem cell and gene therapy 1064*

**165. Robot-assisted Cardiac Surgery ....1066**
Yugal K Mishra, Syed Asrar Ahmed Qadri

*Robot-assisted coronary artery bypass graft 1067*
*Robotic internal mammary harvest 1067*

**166. Aortic Valve Surgery in 2014: Challenges Ahead ....1072**
OP Yadava, A Kundu

*Minimally invasive aortic valve surgery 1072*
*Transcatheter aortic valve implantation 1072*
*Sutureless valves 1074*
*New heart valve designs 1074*
*Imaging 1076*

**167. A New Era in Heart Transplantation with Donation after Circulatory Death ..... 1079**
Manoj Agny

*Warm preservation 1079*
*Donation after circulatory death procedure 1079*
*Clinical trials 1080*
*Ethical angle 1080*
*Comment 1081*

**168. Total Arterial Minimally Invasive CABG in Multivessel Disease—The Nambiar Technique ..... 1082**
Pradeep Nambiar

*Methods 1082*
*Results 1084*
*Comment 1085*

**169. Management of Aortic Dissection and Aneurysms: Recent Advances 2014 ..... 1087**
Devi Prasad Shetty, Binoy Chattuparambil

*Acute aortic syndrome 1087*
*Management of aortic aneurysm 1090*

**SECTION 21: STEM CELL THERAPY**

**170. Potential of Stem Cell Banking in India ..... 1095**
Vinod K Shah, Kavita K Shalia

*Stem cell bank 1095*
*Cord blood cells and cord blood bank 1096*
*Stem cell banking in India 1096*
*Umbilical cord blood transplantation in India 1096*
*Regulatory environment in India and other countries 1097*
*What is the global and Indian scenario of stem cell therapy? 1097*

**SECTION 22: NEW CARDIAC IMAGING MODALITIES**

**171. Cardiac MRI: Promise, Hope, and Hype ..... 1101**
Mona Bhatia

*Technical aspects of cardiac MRI 1101*
*Image acquisition 1101*
*Imaging planes 1102*
*Indications and applications 1102*
*Future developments 1106*

**172. CT Coronary Angiography: Friend or Foe to the Cardiologists? ..... 1108**
Rochita Venkataramanan

*CT angiography is safe, comfortable and accurate 1108*
*Prognostic value of CT angiography for major adverse cardiac events: scoring over the clinical risk model 1108*
*CT angiography value in the emergency room 1109*
*CT angiography usefulness for percutaneuous coronary intervention and thrombolysis 1109*
*CT angiography and CT myocardial perfusion help find the culprit artery 1110*
*Plaque regression assessment by CT angiography 1110*
*CTA and catheter angiogram disagreement on percentage stenosis 1110*
*Appropriateness criteria for CTA 1111*

**173. Clinical Value of SPECT and PET in CAD ..... 1113**
GN Mahapatra
*Clinical application of spect myocardial perfusion imaging 1114*
*Clinical applications of positron emission tomography myocardial perfusion imaging 1115*
*Emerging concepts in clinical applications 1122*

**174. The MOGE(S) Classification of Cardiomyopathy: Is it Relevant in India and Other Low and Middle-income Countries? ..... 1126**
Eloisa Arbustini, Jagat Narula

**SECTION 23: ECMO**

**175. ECMO in ICU ..... 1135**
Yatin Mehta
*Background 1135*
*Aims of ECMO 1135*
*ECMO terminology 1135*
*Decision to institute ECMO 1135*
*Contraindication of ECMO 1135*
*Types of ECMO 1136*
*VV ECMO 1137*
*VA ECMO 1138*
*Central versus peripheral ECMO 1139*
*Uses of ECMO 1140*
*ECMO for cardiac surgery 1140*
*ECMO in cardiogenic shock 1140*
*ECMO in heart failure 1140*
*ECMO and sepsis 1141*
*Noncardiac indications for ECMO 1143*
*Acute respiratory distress syndrome 1143*
*Clinical trials 1143*
*ECMO and CRRT 1143*
*ECMO and organ preservation 1144*
*ECMO and lung transplantation 1145*
*Meconium aspiration and ECMO 1147*
*Novoseven use in a noncardiac pediatric ECMO patient with uncontrolled bleeding 1147*
*Circuit management 1147*
*Past and future of ECMO: the cardiohelp 1149*
*ILA activve® (Novalung, Germany) for $CO_2$ removal during ECMO 1150*
*Complications 1150*

**176. Echocardiography in Extracorporeal Membrane Oxygenation ..... 1152**
Poonam Malhotra
*Types of ECMO 1152*
*Indications of VV ECMO and VA ECMO 1152*
*Cardiac indications of ECMO 1153*
*Venoarterial ECMO versus ventricular assist device 1154*
*Venoarterial ECMO for cardiorespiratory failure 1155*
*ECMO as bridge to transplant 1155*
*Venoarterial ECMO contraindications 1155*
*Quantification of differential ECMO return flow through an axillary artery anastomosis graft with spectral Doppler echocardiography 1155*

*Echocardiography has a pivotal role throughout the care of patient's support on ECMO 1156*
*Echocardiography before ECMO commencement (selection of patients) 1156*
*Echocardiography during ECMO initiation and cannulation 1158*
*Echocardiography and monitoring ECMO response 1163*
*Echocardiography in detection of ECMO complications 1166*
*Echocardiography during patient's recovery and weaning of support 1169*
*Pitfalls of echo in ECMO 1171*
*Echo is fundamental during ECMO in following ways 1171*

**SECTION 24: MISCELLANEOUS**

**177. Medicolegal and Ethical Issues in Cardiology Practice: How to Defend a Complaint and/or a Judgment against a Doctor for Alleged Professional Misconduct? ..... 1175**
KK Aggarwal
*Defenses in professional misconduct 1175*

**178. Biostatistics: What a Cardiologist Should Know? ..... 1181**
Sada Nand Dwivedi
*Background 1181*
*Scales of measurements 1181*
*Major steps under research methodology 1181*
*Data collection: bias, confounding and effect modification 1183*

**179. How to Be a Good Cardiologist? ..... 1186**
RP Sapru
*Professional attributes 1186*
*Academic attributes 1188*
*Personal attributes 1188*
*Social attributes 1188*

**180. Hemodynamic Features of Constrictive Physiology ..... 1190**
V Jacob Jose
*Classical or traditional hemodynamic features of constrictive physiology 1190*

**181. Corus CAD Test: A Gene Expression Test to Help Exclude the Diagnosis of Obstructive Coronary Artery Disease ..... 1195**
Mark Monane
*Test description 1196*
*Clinical studies 1196*

**182. Recent Advances in the Pathophysiology of Cardiac Muscle ..... 1201**
RK Kotokey, Patil Vijay Kumar, Nayanjyoti Bez, Atul Pandey, Sayyed Imran, Luhamdao Bathari

**183. Pharmacogenetics and Pharmacogenomics: Future of Cardiovascular Therapeutics ..... 1204**
Ranjith MP, Divya Raj R, Dourado PMM
*Statins: variability in efficacy and risk of myopathy 1204*
*Antiplatelet drug resistance 1205*
*Oral anticoagulants 1206*
*Beta-blockers 1206*
*Angiotensin-converting enzyme inhibitors 1206*
*Future perspectives 1207*

**184. What the Adult Cardiologist Should Know about Cyanotic Congenital Heart Disease?.....1209**
P Syamasundar Rao
*Tetralogy of Fallot 1209*
*Transposition of the great arteries 1210*
*Truncus arteriosus 1211*
*Total anomalous pulmonary venous connection 1211*
*Tricuspid atresia and other single ventricle lesions 1212*
*Surgical correction in adulthood 1213*

***Index*..... *1217***